drugset / Trial / NCT03058471

Efficacy of Starting Methotrexate Early in Chikungunya Arthritis

NCT03058471

RandomizedCrossoverSingle-blindTreatment

Summary

This is a single center, prospective, randomized controlled open label trial with a one sided cross over design to compare the efficacy of initiating Methotrexate(Mtx) in early post Chikungunya induced arthritis (4-12 weeks after onset) with Non Steroidal Anti inflammatory Drugs(NSAID) alone.

Timeline

Start
2016-12
Primary completion
2017-10
Completion
2018-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methotrexate Small molecule 25 mg
Comparator Methylprednisolone Other / unclassified 80 mg Intramuscular
Comparator Pantoprazole Other / unclassified

Indications